Mutant IDH Inhibitors Induce Lineage Differentiation in IDH-mutant Oligodendroglioma release_w6fpaaeikbebtm3fark45pycfu

by Avishay Spitzer, Simon Gritsch, Hannah Weisman, Nicolas Gonzalez Castro, Masashi Nomura, Nicholas Druck, Rony Chanoch-Myers, Christine Lee, Hiroaki Nagashima, Julie Miller, Isabel Arrillaga-Romany, David Louis (+7 others)

Released as a post by Cold Spring Harbor Laboratory.

2021  

Abstract

Recent data showed promising signs of objective tumor responses in subsets of patients with low grade glioma treated with inhibitors of mutant IDH (IDHi). However, the molecular and cellular underpinnings of such responses are not known. Here, we profiled 6,039 transcriptomes by single-cell or single-nucleus RNA-sequencing isolated from three IDH-mutant oligodendroglioma patients with clinical response to IDHi. Importantly, the tissues were sampled on-drug, four weeks from treatment initiation and our dataset includes a matched pre- and on-treatment sample pair. We integrate our findings with analysis of 8,241 transcriptomes from seven untreated samples, 134 bulk samples from the TCGA and experimental models. We find that IDHi treatment induces a robust differentiation towards glial lineages, accompanied by a depletion of stem-like cells and a reduction of cell proliferation. Our study provides the first evidence in patients of the differentiating potential of IDHi on the cellular hierarchies that drive oligodendrogliomas.
In application/xml+jats format

Archived Files and Locations

application/pdf   6.7 MB
file_dhx55cngqzdirmtm77akw76mji
www.medrxiv.org (repository)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  post
Stage   unknown
Date   2021-11-20
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 50f792bb-94d3-4000-821e-2c32e7358649
API URL: JSON